12/4
07:00 pm
aapg
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Medium
Report
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
12/4
07:04 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
12/1
08:00 am
aapg
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
Neutral
Report
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
11/24
07:00 pm
aapg
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
Low
Report
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
11/24
09:04 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/19
08:00 am
aapg
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Low
Report
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
11/10
08:03 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
11/6
06:56 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/5
06:01 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
11/3
08:10 pm
aapg
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
Medium
Report
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
11/3
08:10 pm
aapg
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
Medium
Report
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
10/29
08:00 pm
aapg
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
Low
Report
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
10/7
08:00 am
aapg
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
Medium
Report
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025